Effect of Nandrolone Decanoate on Disuse Muscle Atrophy and Bone Healing in Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2005
S.J. Yun; J.H. Lim; Y.E. Byeon; O.K. Kweon

This study was performed to evaluate the effects of nandrolone decanoate (ND) on immobilized skeletal muscle atrophy and on bone healing in dogs.

Twenty adult dogs (3.3kg~5.5kg and 2~4 years) were divided into three groups according to the amount of ND (Deca-Durabolin® 50mg/ml, Hanhwa Co., Korea) administered; no treatment (group A), 1.5mg/kg ND (group B) and 7.5mg/kg ND (group C). The radius was excised 1mm in length with oscillating bone saw just below the pronator teres muscle and fixed with a plate. ND was injected intramuscularly once a week for 8 weeks from the day of surgery. Robert John's bandage was applied to the dogs. Body weight was measured using electric balance and muscle mass with tapeline at proximal one fourth of the antebrachium immediately after surgery, 2, 4 and 8 weeks. Bone healing was evaluated by radiography and histological examination.

The change rates of muscle mass at 8 weeks in the groups A, B and C were -2.75±0.16%, 1.68±0.11% and 1.74±0.48%, compared to the initial muscle mass, respectively. The increments of muscle mass at 4 and 8 weeks were significantly different between control and the treated groups (p<0.05). There was no significant difference between low and high dose treated groups. More fibrous and connective tissue layer between the fractured gaps were appeared in the treated groups, particularly in group C than the control at 4 weeks. However, there was no difference in evaluation of bone healing among all groups at 8 weeks.

The present study suggested that ND was effective for immobilized disuse muscle atrophy in dogs.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.H. Lim


MAIN : Abstracts, Poster : Effect of Nandrolone Decanoate
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27